|Bid||6.60 x 2900|
|Ask||6.62 x 1300|
|Day's range||5.88 - 6.66|
|52-week range||3.07 - 23.42|
|Beta (5Y monthly)||1.44|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.83|
The days grew shorter last month, as did investors' patience with this synthetic-biology specialist.
Consistent with the falling temperatures outside, investors are turning a cold shoulder to synthetic biology specialist Amyris (NASDAQ: AMRS) this week. As of the close of the trading session on Thursday, shares of Amyris have plunged 47% from their closing price of $14.09 last Friday. Beginning the week on an inauspicious note, Amyris reported third-quarter 2021 earnings after the market closed on Monday.
Failing to deliver on both the top and bottom lines, synthetic-biology specialist Amyris (NASDAQ: AMRS) reported disappointing third-quarter 2021 earnings results yesterday after the market closed. In addition, investors are selling shares after learning that the company is raising capital through the issuance of senior convertible notes. Although the company reported a year-over-year sales increase of 39.7%, it didn't seem to be enough to satisfy investors' appetites.